Wire flash
Berry Genomics Hits Daily Limit Up on Sept 24, Net Inflow of 156M Yuan from Main Forces
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
According to a report by Stockstar (证券之星), Berry Genomics (贝瑞基因) hit its daily price limit (涨停) on September 24, closing at 11.01 yuan. The stock reached the limit at 9:32 AM and remained closed for the session, with a sealing order of 43.6844 million yuan, representing 1.18% of its circulating market value. In terms of fund flows on September 24, main capital (主力资金) saw a net inflow of 156 million yuan, accounting for 50.96% of total turnover. In contrast, speculative capital (游资) recorded a net outflow of 71.8467 million yuan (23.46% of total turnover), and retail investors (散户) had a net outflow of 84.179 million yuan (27.49% of total turnover). The stock is identified as a hot concept stock in the areas of optimizing fertility (three-child policy), precision medicine, and gene sequencing. The report notes that the information is compiled from public sources and is for reference only, not constituting investment advice.
Source report
Closing Price: 11.01 CNY Limit Up Triggered: 9:32 AM (remained closed throughout the session) Locked-in Capital at Close: 43.6844 million CNY, representing 1.18% of its circulating market value
Capital Flow Data (September 24)
| Capital Type | Net Flow (CNY) | % of Total Turnover | |--------------|----------------|---------------------| | Main force (institutional) | +156 million | 50.96% | | Retail (hot money) | -71.8467 million | 23.46% | | Retail (individual) | -84.179 million | 27.49% |
For a breakdown of capital flows over the past five trading days, refer to the table below.
Related Concepts
The stock is a hot-concept play in the following areas:
- Optimized childbirth (three-child policy)
- Precision medicine
- Gene sequencing
Note: The above content is compiled by Securities Star based on publicly available information. It is for reference only and does not constitute investment advice.
Source
证券之星-机会挖掘Eastern